Reata Pharmaceuticals, Inc. - (RETA): Price and Financial Metrics

Reata Pharmaceuticals, Inc. - (RETA)

Today's Latest Price: $157.26 USD

5.37 (3.54%)

Updated Nov 27 1:00pm

Add RETA to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RETA Stock Summary

  • For RETA, its debt to operating expenses ratio is greater than that reported by just 0.52% of US equities we're observing.
  • RETA's price/sales ratio is 626.99; that's higher than the P/S ratio of 99.03% of US stocks.
  • With a year-over-year growth in debt of -100%, Reata Pharmaceuticals Inc's debt growth rate surpasses only 0% of about US stocks.
  • Stocks that are quantitatively similar to RETA, based on their financial statements, market capitalization, and price volatility, are VBIV, VXRT, SAGE, MXL, and RVNC.
  • Visit RETA's SEC page to see the company's official filings. To visit the company's web site, go to

RETA Stock Price Chart Interactive Chart >

Price chart for RETA

RETA Price/Volume Stats

Current price $157.26 52-week high $257.96
Prev. close $151.89 52-week low $88.17
Day low $153.05 Volume 127,700
Day high $157.69 Avg. volume 356,623
50-day MA $127.31 Dividend yield N/A
200-day MA $142.95 Market Cap 5.33B

Reata Pharmaceuticals, Inc. - (RETA) Company Bio

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company was founded in 2002 and is based in Irving, Texas.

RETA Latest News Stream

Event/Time News Detail
Loading, please wait...

RETA Latest Social Stream

Loading social stream, please wait...

View Full RETA Social Stream

Latest RETA News From Around the Web

Below are the latest news stories about Reata Pharmaceuticals Inc that investors may wish to consider to help them evaluate RETA as an investment opportunity.

Reata Pharmaceuticals Can Rally

"Nowadays most people die of a sort of creeping common sense, and discover when it is too late that the only things one never regrets are one's mistakes.”― Oscar Wilde When we last looked at Reata Pharmaceuticals, Inc. (RETA), it had two assets in the clinic that were entering or...

Bret Jensen on Seeking Alpha | September 21, 2020

Reata Pharma down 32% on potential roadblock on omaveloxolone in rare neurodegenerative disorder

Despite its Q2 beat, Reata Pharmaceuticals ([[RETA]] -31.7%) is down out the gate on the heels of its update on omaveloxolone for Friedreich’s Ataxia ((FA)), a rare genetic disease that causes difficulty walking, a loss of sensation in the arms and legs, and impaired speech. There is a risk that the filing...

Seeking Alpha | August 10, 2020

Earnings Scheduled For August 10, 2020

Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. • Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is exp...

Benzinga | August 10, 2020

Reata Announces the Appointment of Martin W. Edwards, M.D. to Its Board of Directors

PLANO, Texas, July 30, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointment of Martin W. Edwards, M.D. to its Board of Directors, effective August 3, 2020.  Since 2003, Dr. Edwards has held various positions at Novo Holdings, a life sciences investment firm, and most recently, he has served as a part-time Senior Partner.  Earlier in his career, he was Corporate VP and Global Head of Drug Development for Novo Nordisk, where he led all aspects of pre-clinical and clinical drug development.  Dr. Edwards currently serves on the board of directors of three publicly traded pharmaceutical companies, Inozyme Pharma, Inc., Kalvista Pharmaceuticals, Inc., and Verona Pharm...

Yahoo | July 30, 2020

Did Hedge Funds Make The Right Call On Reata Pharmaceuticals, Inc. (RETA) ?

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | July 13, 2020

Read More 'RETA' Stories Here

RETA Price Returns

1-mo 34.74%
3-mo 49.84%
6-mo 12.06%
1-year -19.41%
3-year 519.13%
5-year N/A
YTD -23.07%
2019 264.40%
2018 98.09%
2017 29.73%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9254 seconds.